Published in J Clin Oncol on January 01, 1990
High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer (1993) 0.85
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats. Toxicol Pathol (2014) 0.82
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res (2014) 0.80
Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol (1991) 0.77
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer (1994) 0.77
Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma. Sarcoma (1999) 0.75
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. J Cancer Res Clin Oncol (1997) 0.75
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. J Cancer Res Clin Oncol (1991) 0.75
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. J Cancer Res Clin Oncol (1991) 0.75
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. J Cancer Res Clin Oncol (1991) 0.75
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. J Cancer Res Clin Oncol (1991) 0.75
Racial differences in the treatment of early-stage lung cancer. N Engl J Med (1999) 9.65
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
The influence of hospital volume on survival after resection for lung cancer. N Engl J Med (2001) 4.83
Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics (1983) 4.51
Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making (1985) 4.47
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst (2001) 3.65
Biases in the assessment of diagnostic tests. Stat Med (1987) 3.48
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst (1996) 3.23
Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA (2000) 3.18
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry (1992) 2.84
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. J Clin Oncol (2001) 2.43
A general regression methodology for ROC curve estimation. Med Decis Making (1988) 2.37
A treatment allocation procedure for sequential clinical trials. Biometrics (1980) 2.26
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 2.10
North American Multicenter Study on flow cytometric enumeration of CD34+ hematopoietic stem cells. J Hematother (1996) 2.03
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg (1996) 1.91
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res (1978) 1.88
Clinical trials with adriamycin. Cancer (1971) 1.86
Spilled gallstones after laparoscopic cholecystectomy. A relevant problem? A retrospective analysis of 10,174 laparoscopic cholecystectomies. Surg Endosc (1998) 1.77
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
A lesson from Canada: Ontario's health insurance. N Engl J Med (1978) 1.76
Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol (1998) 1.74
Carcinoembryonic antigen: clinical correlation with chemotherapy for metastatic gastrointestinal cancer. Cancer (1974) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs Shouldice herniorrhaphy. Early results. Surg Endosc (1996) 1.71
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol (1989) 1.69
The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. EMBO J (1995) 1.69
Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing. Med Decis Making (1990) 1.68
Treatment allocation methods in clinical trials: a review. Stat Med (1985) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Complications of laparoscopic cholecystectomy in Switzerland. A prospective 3-year study of 10,174 patients. Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc (1998) 1.65
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis (2001) 1.58
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol (1999) 1.57
Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol (1994) 1.55
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res (1967) 1.44
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet (1988) 1.43
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Construction of receiver operating characteristic curves when disease verification is subject to selection bias. Med Decis Making (1984) 1.41
Diamond's correction method--a real gem or just cubic zirconium? Med Decis Making (1991) 1.40
Crystal structure of the FAD/NADPH-binding domain of rat neuronal nitric-oxide synthase. Comparisons with NADPH-cytochrome P450 oxidoreductase. J Biol Chem (2001) 1.39
Complex regulation of early paired expression: initial activation by gap genes and pattern modulation by pair-rule genes. Development (1993) 1.39
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res (1983) 1.39
[Early results of the initial 100 laparoscopic hernia operations under peridural anesthesia]. Schweiz Med Wochenschr (1995) 1.39
Preoperative Nyhus classification of inguinal hernias and type-related individual hernia repair. A case for diagnostic laparoscopy. Surg Laparosc Endosc (1997) 1.39
Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res (1976) 1.38
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther (1972) 1.35
The association of patients' socioeconomic characteristics with the length of hospital stay and hospital charges within diagnosis-related groups. N Engl J Med (1988) 1.34
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res (1969) 1.33
Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials (1980) 1.32
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest (1997) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. Cancer (1968) 1.28
Optimal sample size for a series of pilot trials of new agents. Biometrics (1996) 1.28
The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol (2001) 1.27
Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Ann Intern Med (1973) 1.27
The National Cancer Chemotherapy Program. Science (1982) 1.26
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Current concepts: malignant mesothelioma. N Engl J Med (1980) 1.24
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood (1965) 1.23
Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell (1980) 1.23
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
double-time is identical to discs overgrown, which is required for cell survival, proliferation and growth arrest in Drosophila imaginal discs. Development (1999) 1.23
The effect of skin homograft rejection on recipient and donor mixed leukocyte cultures. J Exp Med (1965) 1.22
The impact of treatment allocation procedures on nominal significance levels and bias. Control Clin Trials (1987) 1.22
Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother (1965) 1.22
Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) (1979) 1.21
Cell proliferation in human melanoma. J Clin Invest (1970) 1.21
Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med (1989) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
shaven and sparkling are mutations in separate enhancers of the Drosophila Pax2 homolog. Development (1998) 1.18
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer (1972) 1.18
Osteosarcoma: fifteen years later. N Engl J Med (1985) 1.17
The use of ambulatory testing in prepaid and fee-for-service group practices. Relation to perceived profitability. N Engl J Med (1986) 1.16
A measure to aid in the interpretation of published clinical trials. Stat Med (1985) 1.15